FXR modulators for enterohepatic and metabolic diseases

References

• Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010;8:e005.
   PubMedGoogle Scholar
• Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81:687–693.
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543–553.
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225.
   PubMed Web of Science ®Google Scholar
• Wang H, Cao G, Wang G, et al. Regulation of mammalian UDP-glucuronosyltransferases. Curr Drug Metab. 2018;19:490–501.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148:751–761.
   PubMed Web of Science ®Google Scholar
• Van Mil SW, Milona A, Dixon PH, et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology. 2007;133:507–516.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li F, Zalzala M, et al. Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology. 2016;64:1072–1085.
   PubMed Web of Science ®Google Scholar
• Claudel T, Inoue Y, Barbier O, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003;125:544–555.
   PubMed Web of Science ®Google Scholar
• Xu J, Li Y, Chen WD, et al. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology. 2014;59:1761–1771.
   PubMed Web of Science ®Google Scholar
• Pineda Torra I, Claudel T, Duval C, et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol. 2003;17:259–272.
   PubMed Web of Science ®Google Scholar
• Liu N, Zhao J, Wang J, et al. Farnesoid X receptor ligand CDCA suppresses human prostate cancer cells growth by inhibiting lipid metabolism via targeting sterol response element binding protein 1. Am J Transl Res. 2016;8:5118–5124.
   PubMed Web of Science ®Google Scholar
• Dong B, Young M, Liu X, et al. Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters. J Lipid Res. 2017;58:350–363.
   PubMed Web of Science ®Google Scholar
• Xiong X, Wang X, Lu Y, et al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol. 2014;60:847–854.
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest. 2006;116:1102–1109.
   PubMed Web of Science ®Google Scholar
• Trabelsi MS, Daoudi M, Prawitt J, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015;6:7629.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu HX, Zhang M, et al. Fatty liver diseases, bile acids, and FXR. Acta Pharmaceutica Sinica B. 2016;6:409–412.
   PubMed Web of Science ®Google Scholar
• Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509:183-+.
   PubMed Web of Science ®Google Scholar
• Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21:159–165.
   PubMed Web of Science ®Google Scholar
• Li F, Jiang CT, Krausz KW, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4:2384.
   PubMed Web of Science ®Google Scholar
• Pathak P, Cen X, Nichols RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. 2018: published online 27 February 2018, doi:10.1002/hep.29857.
   PubMed Web of Science ®Google Scholar
• Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6:10166.
   PubMed Web of Science ®Google Scholar
• Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008;48:1632–1643.
   PubMed Web of Science ®Google Scholar
• Kim DH, Xiao Z, Kwon S, et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. Embo J. 2015;34:184–199.
   PubMed Web of Science ®Google Scholar
• Hao H, Cao L, Jiang C, et al. Farnesoid X receptor regulation of the NLRP3 inflammasome enderlies cholestasis-associated sepsis. Cell Metab. 2017;25:856–867 e855.
   PubMed Web of Science ®Google Scholar
• Radreau P, Porcherot M, Ramiere C, et al. Reciprocal regulation of farnesoid X receptor alpha activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes. FASEB J. 2016;30:3146–3154.
   PubMed Web of Science ®Google Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Rizzo G, Antonelli E, et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther. 2005;315:58–68.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Rizzo G, Antonelli E, et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther. 2005;314:584–595.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014;59:2286–2298.
   PubMed Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Seeland BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017;66:724–733.
   PubMed Web of Science ®Google Scholar
• Xie Y, Wang H, Cheng X, et al. Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci Rep. 2016;6:18751.
   PubMed Web of Science ®Google Scholar
• Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science. 2006;312:233.
   PubMed Web of Science ®Google Scholar
• Borude P, Edwards G, Walesky C, et al. Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology. 2012;56:2344–2352.
   PubMed Web of Science ®Google Scholar
• Naugler WE, Tarlow BD, Fedorov LM, et al. Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology. 2015;149:728–740.
   PubMed Web of Science ®Google Scholar
• Li GD, Guo GL. Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration. Acta Pharmaceutica Sinica B. 2015;5:93–98.
   PubMed Web of Science ®Google Scholar
• Lee JM, Wagner M, Xiao R, et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature. 2014;516:112–115.
   PubMed Web of Science ®Google Scholar
• Meng Z, Wang X, Gan Y, et al. Deletion of IFNgamma enhances hepatocarcinogenesis in FXR knockout mice. J Hepatol. 2012;57:1004–1012.
   PubMed Web of Science ®Google Scholar
• Sepe V, Distrutti E, Fiorucci S, et al. Farnesoid X receptor modulators 2014-present: a patent review. Expert Opin Ther Pat. 2018;28:351–364.
   PubMed Web of Science ®Google Scholar
• Sepe V, Distrutti E, Fiorucci S, et al. Farnesoid X receptor modulators (2011-2014): a patent review. Expert Opin Ther Pat. 2015;25:885–896.
   PubMed Web of Science ®Google Scholar
• Crawley ML. Farnesoid X receptor modulators: a patent review. Expert Opin Ther Pat. 2010;20:1047–1057.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Gioiello A, Costantino G, et al. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. J Med Chem. 2006;49:4208–4215.
   PubMed Web of Science ®Google Scholar
• Gioiello A, Cerra B, Mostarda S, et al. Bile acid derivatives as ligands of the farnesoid X receptor: molecular determinants for bile acid binding and receptor modulation. Curr Top Med Chem. 2014;14:2159–2174.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569.
   PubMed Web of Science ®Google Scholar
• Intercept Pharmaceuticals. Preparation, uses and solid forms of obeticholic acid. WO2013192097. 2013.
   Google Scholar
• Concert Pharmaceuticals. Deuterated obeticholic acid for treating diseases that are beneficially treated by farnesoid X receptor agonists. WO2017111979. 2016.
   Google Scholar
• Intercept Pharmaceuticals. Novel steroid agonist for FXR. WO2005082925. 2005.
   Google Scholar
• Rizzo G, Passeri D, De Franco F, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol. 2010;78:617–630.
   PubMed Web of Science ®Google Scholar
• Intercept Pharmaceuticals. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated deseases or conditions. WO2008002573. 2008.
   Google Scholar
• Gioiello A, Macchiarulo A, Carotti A, et al. Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3alpha,7alpha-dihydroxy-6alpha-ethyl-24-nor-5beta-cholan-23-amine. Bioorg Med Chem. 2011;19:2650–2658.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Tamehiro N, Sato Y, et al. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J Pharm Sci. 2008;107:285–294.
   Web of Science ®Google Scholar
• Pellicciari R, Passeri D, De Franco F, et al. Discovery of 3alpha,7alpha,11beta-Trihydroxy-6alpha-ethyl-5beta-cholan-24-oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for enterohepatic disorders. J Med Chem. 2016.
   PubMedGoogle Scholar
• Deng R, Yang D, Yang J, et al. Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor. J Pharmacol Exp Ther. 2006;317:317–325.
   PubMed Web of Science ®Google Scholar
• Soisson SM, Parthasarathy G, Adams AD, et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc Natl Acad Sci USA. 2008;105:5337–5342.
   PubMed Web of Science ®Google Scholar
• Wang S, Lai K, Moy FJ, et al. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Endocrinology. 2006;147:4025–4033.
   PubMed Web of Science ®Google Scholar
• Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem. 2000;43:2971–2974.
   PubMed Web of Science ®Google Scholar
• Glaxo Group Ltd. Assays for ligands for nuclear receptors. WO2000037077. 2000.
   Google Scholar
• Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW4064. Bioorg Med Chem Lett. 2008;18:4339–4343.
   PubMed Web of Science ®Google Scholar
• Bass JY, Caravella JA, Chen L, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg Med Chem Lett. 2011;21:1206–1213.
   PubMed Web of Science ®Google Scholar
• Abel U, Schluter T, Schulz A, et al. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg Med Chem Lett. 2010;20:4911–4917.
   PubMed Web of Science ®Google Scholar
• Kinzel O, Steeneck C, Schluter T, et al. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties. Bioorg Med Chem Lett. 2016;26:3746–3753.
   PubMed Web of Science ®Google Scholar
• Phenex Pharmaceuticals AG. Novel FXR (NR1H4) binding and activity modulating compounds. WO2011020615. 2011.
   Google Scholar
• Liles JT, Karnik S, Hambruch E, et al. FXR agonism by GS-9674 decreases steatosis and fibrosis in a murine model of NASH. J Hepatol. 2016;64:S169.
   Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Supper P, et al. The non-steroidal FXR agonist GS-9674 reduces liver fibrosis and ameliorates portal hypertension in a rat NASH model. J Hepatol. 2016;64:S165–S166.
   Web of Science ®Google Scholar
• Nelson CH, Kirby BJ, Lu N, et al. Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects. J Hepatol. 2017;66:S151–S152.
   Web of Science ®Google Scholar
• Smalley TL, Boggs S, Caravella JA, et al. Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists. Bioorg Med Chem Lett. 2015;25:280–284.
   PubMed Web of Science ®Google Scholar
• Flesch D, Gabler M, Lill A, et al. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties. Bioorg Med Chem. 2015;23:3490–3498.
   PubMed Web of Science ®Google Scholar
• Novartis AG Methods for using FXR agonists. WO2017145041. 2017.
   Google Scholar
• Tully DC, Rucker PV, Chianelli D, et al. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic Liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem. 2017;60:9960–9973.
   PubMed Web of Science ®Google Scholar
• Badman MK, Desai S, Laffitte B, et al. First-in-Human experience with LJN452, an orally available non-bile acid FXR agonist, demonstrates potent activation of FXR in healthy subjects. Hepatology. 2016;64:16a–17a.
   PubMed Web of Science ®Google Scholar
• D M, V MA, R AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Molecular Cell. 2003;11:1079–1092.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao Z, Zhou J, et al. A novel intestinal-restricted FXR agonist. Bioorg Med Chem Lett. 2017;27:3386–3390.
   PubMed Web of Science ®Google Scholar
• China Pharmaceutical University. Synthesis and applications of novel FXR agonists. CN106518708. 2017.
   Google Scholar
• Wyeth. FXR agonists for the treatment of malignancies. US20080299118. 2008.
   Google Scholar
• Wyeth. 1,4,5,6-tetrahydro-pyrrolo[2,3-d]azepines and imidazo[4,5-d]azepines as modulators of nuclear receptor activity. US20090137554. 2009.
   Google Scholar
• Mehlmann JF, Crawley ML, Lundquist J, et al. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorg Med Chem Lett. 2009;19:5289–5292.
   PubMed Web of Science ®Google Scholar
• Ricketts ML, Boekschoten MV, Kreeft AJ, et al. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. Mol Endocrinol. 2007;21:1603–1616.
   PubMed Web of Science ®Google Scholar
• Howard WR, Pospisil JA, Njolito E, et al. Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor. Toxicol Appl Pharmacol. 2000;163:195–202.
   PubMed Web of Science ®Google Scholar
• Joly S, Porcherot M, Radreau P, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol. 2017;66:S690.
   Web of Science ®Google Scholar
• Erstad DJ, Farrar CT, Masia R, et al. A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis. J Hepatol. 2017;66:S165.
   Web of Science ®Google Scholar
• An P, Vaid K, Wei G, et al. A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease. J Hepatol. 2017;66:S657.
   PubMed Web of Science ®Google Scholar
• Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17:225–235.
   PubMed Web of Science ®Google Scholar
• Nishimaki-Mogami T, Kawahara Y, Tamehiro N, et al. 5Alpha-bile alcohols function as farnesoid X receptor antagonists. Biochem Biophys Res Commun. 2006;339:386–391.
   PubMed Web of Science ®Google Scholar
• Carter BA, Taylor OA, Prendergast DR, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res. 2007;62:301.
   PubMed Web of Science ®Google Scholar
• Choi H, Hwang H, Chin J, et al. Tuberatolides, potent FXR antagonists from the Korean marine tunicate botryllus tuberatus. J Nat Prod. 2011;74:90–94.
   PubMed Web of Science ®Google Scholar
• Xu X, Xu X, Liu P, et al. Structural basis for small molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a selective antagonist of farnesoid X receptor alpha (FXRalpha) in stabilizing the homodimerization of the receptor. J Biol Chem. 2015;290:19888–19899.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Compounds and methods for modulating FXR. WO2009012125. 2009.
   Google Scholar
• Jin L, Feng X, Rong H, et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun. 2013;4:1937.
   PubMed Web of Science ®Google Scholar
• Kaimal R, Song X, Yan B, et al. Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones. J Pharmacol Exp Ther. 2009;330:125–134.
   PubMed Web of Science ®Google Scholar
• Li GD, Lin WW, Araya JJ, et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharm. 2012;258:268–274.
   PubMed Web of Science ®Google Scholar
• Massafra V, Pellicciari R, Gioiello A, et al. Progress and challenges of selective farnesoid X receptor modulation. Pharmacol Ther. 2018: published online 20 Jun 2018, doi: 10.1016/j.pharmthera.2018.06.009.
   PubMedGoogle Scholar
• Cui J, Huang L, Zhao A, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem. 2003;278:10214–10220.
   PubMed Web of Science ®Google Scholar
• Zhao A, Yu J, Lew JL, et al. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol. 2004;23:519.
   PubMed Web of Science ®Google Scholar
• Amarin Phaimaceuticals Ireland Ltd. Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis. US20140187633. 2014.
   Google Scholar
• Vanhoecke B, Derycke L, Van Marck V, et al. Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer. 2005;117:889–895.
   PubMed Web of Science ®Google Scholar
• Dussault I, Beard R, Lin M, et al. Identification of gene-selective modulators of the bile acid receptor FXR. J Biol Chem. 2003;278:7027–7033.
   PubMed Web of Science ®Google Scholar
• Bijsmans IT, Guercini C, Ramos Pittol JM, et al. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Sci Rep. 2015;5:14086.
   PubMed Web of Science ®Google Scholar
• Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002;277:2908–2915.
   PubMed Web of Science ®Google Scholar
• Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem. 2001;276:28857–28865.
   PubMed Web of Science ®Google Scholar
• Huo XK, Liu J, Yu ZL, et al. Alisma orientale extract exerts the reversing cholestasis effect by activation of farnesoid X receptor. Phytomedicine. 2018;42:34–42.
   PubMed Web of Science ®Google Scholar
• Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112:1678–1687.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Clerici C, Antonelli E, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005;313:604–612.
   PubMed Web of Science ®Google Scholar
• Ali AH, Lindor KD. Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opin Pharmacother. 2016;17:1809–1815.
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.
   PubMed Web of Science ®Google Scholar
• Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–11049.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010;51:771–784.
   PubMed Web of Science ®Google Scholar
• Roth JD, Feigh M, Veidal SS, et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol. 2018;24:195–210.
   PubMed Web of Science ®Google Scholar
• Kremoser C, Hambruch E, Deuschle U, et al. Novel FXR agonists with potent lipid lowering, insulin sensitising, anti-inflammatory and anti-fibrotisation effects in mouse models of metabolic syndrome and NASH. J Hepatol. 2011;54:S44.
   Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129.
   PubMed Web of Science ®Google Scholar
• Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497–1512.
   PubMed Web of Science ®Google Scholar
• Schwabl P, Hambruch E, Payer BA, et al. The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats. J Hepatol. 2015;62:S238.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380–388.
   PubMed Web of Science ®Google Scholar
• Liu N, Meng Z, Lou G, et al. Hepatocarcinogenesis in FXR−/− mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol Endocrinol. 2012;26:775–785.
   PubMedGoogle Scholar
• Jiang Y, Iakova P, Jin J, et al. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology. 2013;57:1098–1106.
   PubMed Web of Science ®Google Scholar
• Deuschle U, Schuler J, Schulz A, et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One. 2012;7:e43044.
   PubMed Web of Science ®Google Scholar
• Cariello M, Peres C, Zerlotin R, et al. Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(-/-) mice. Sci Rep. 2017;7:11203.
   PubMed Web of Science ®Google Scholar
• Attinkara R, Mwinyi J, Truninger K, et al. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes. 2012;5:461.
   PubMedGoogle Scholar
• Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60:463–472.
   PubMed Web of Science ®Google Scholar
• Lieu T, Jayaweera G, Zhao P, et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology. 2014;147:1417–1428.
   PubMed Web of Science ®Google Scholar
• Verbeke L, Nevens F, Laleman W. Steroidal or non-steroidal FXR agonists - Is that the question? J Hepatol. 2017;66:680–681.
   PubMed Web of Science ®Google Scholar
• Modica S, Petruzzelli M, Bellafante E, et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology. 2012;142:355–365.
   PubMed Web of Science ®Google Scholar
• China Pharmaceutical University. Application of FXR agonist and apoptosis inhibitor combination in preparing superior anti-hepatic fibrosis drug. CN108114284. 2018.
   Google Scholar
• Sumitomo Dainippon Pharma. Combination drug for nonalcoholic steatohepatitis comprising farnesoid X receptor agonist and angiotensin II receptor antagonist. WO2017170434. 2017.
   Google Scholar
• Modunex Bio Corp. Combination therapy for nonalcoholic steatohepatitis (NASH) and liver fibrosis. WO2018126016. 2018.
   Google Scholar